Search results for "result"

showing 10 items of 2426 documents

First trimester biochemical screening for Down's syndrome in singleton pregnancies conceived by assisted reproduction

2005

BACKGROUND: Serum biochemical markers [free betahCG (fbetahCG); pregnancy-associated plasma protein-A (PAPP-A)] used in first trimester Down's syndrome screening have not been fully investigated in pregnancies achieved by assisted reproduction techniques. We present data on pregnancies conceived by all types of assisted reproduction techniques, including pregnancies following ovum donation (OD) and a large sample by ICSI. METHODS: First trimester Down's syndrome screening was performed in 1054 normal singleton pregnancies: natural conception (n = 498), ovulation induction (OS, n = 97), IVF (n = 47), ICSI (n = 222) and OD (n = 190). RESULTS: No differences in maternal levels of fbetahCG and …

Down syndromemedicine.medical_specialtyReproductive Techniques AssistedPregnancy-associated plasma protein Amedicine.medical_treatmentPrenatal diagnosisBiologyPreimplantation genetic diagnosisEmbryo cryopreservationPregnancyPrenatal DiagnosismedicineHumansChorionic Gonadotropin beta Subunit HumanFalse Positive ReactionsGynecologyPregnancyurogenital systemObstetricsRehabilitationReproducibility of ResultsObstetrics and GynecologyGestational agemedicine.diseasePregnancy Trimester FirstReproductive MedicineFemaleOvulation inductionDown SyndromeBiomarkersHuman Reproduction
researchProduct

First Measurement of Transverse-Spin-Dependent Azimuthal Asymmetries in the Drell-Yan Process

2017

The first measurement of transverse-spin-dependent azimuthal asymmetries in the pion-induced Drell-Yan (DY) process is reported. We use the CERN SPS 190 GeV/$c$, $\pi^{-}$ beam and a transversely polarized ammonia target. Three azimuthal asymmetries giving access to different transverse-momentum-dependent (TMD) parton distribution functions (PDFs) are extracted using dimuon events with invariant mass between 4.3 GeV/$c^2$ and 8.5 GeV/$c^2$. The observed sign of the Sivers asymmetry is found to be consistent with the fundamental prediction of Quantum Chromodynamics (QCD) that the Sivers TMD PDFs extracted from DY have a sign opposite to the one extracted from semi-inclusive deep-inelastic sc…

Drell-Yan process550ComputerSystemsOrganization_COMPUTERSYSTEMIMPLEMENTATIONNuclear TheoryGeneral Physics and Astronomyparton: distribution functiontransverse momentum dependence01 natural sciencesCOMPASSHigh Energy Physics - ExperimentSivers functionHigh Energy Physics - Experiment (hep-ex)semi-inclusive reaction [deep inelastic scattering]High Energy Physics - Phenomenology (hep-ph)ddc:550[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Nuclear ExperimenttransversityPhysicsQuantum chromodynamics(muon+ muon-) [mass spectrum]Large Hadron Colliderdeep inelastic scattering: semi-inclusive reactionpolarized target: transverse190 GeV/ctransverse [polarized target]nucleonDrell–Yan processhep-phdimuon: mass spectrumAzimuthHigh Energy Physics - PhenomenologyTransverse planeasymmetry [angular distribution]pi- nucleus: scatteringmass spectrum [dimuon]distribution function [parton]Nucleonspin: asymmetryParticle Physics - ExperimentParticle physicsangular distribution: asymmetryscattering [pi- nucleus]ComputingMethodologies_IMAGEPROCESSINGANDCOMPUTERVISIONFOS: Physical sciencesComputerApplications_COMPUTERSINOTHERSYSTEMSAccelerator Physics and InstrumentationGeneralLiterature_MISCELLANEOUSNuclear physicsPhysics and Astronomy (all)[ PHYS.HEXP ] Physics [physics]/High Energy Physics - Experiment [hep-ex]0103 physical sciencesquantum chromodynamicsuniversality010306 general physicsParticle Physics - Phenomenology010308 nuclear & particles physicshep-exHigh Energy Physics::PhenomenologyAcceleratorfysik och instrumenteringCERN SPSmass spectrum: (muon+ muon-)ComputingMethodologies_PATTERNRECOGNITION[PHYS.HPHE]Physics [physics]/High Energy Physics - Phenomenology [hep-ph]Physics::Accelerator Physics[ PHYS.HPHE ] Physics [physics]/High Energy Physics - Phenomenology [hep-ph]High Energy Physics::Experimentasymmetry [spin]experimental results
researchProduct

Tevatron Run II combination of the effective leptonic electroweak mixing angle

2018

The Ministry of Science and Innovation and the Consolider-Ingenio 2010 Program and the European Union community Marie Curie Fellowship Contract No. 302103.

Drell-Yan processsemianalytical programsPhysics and Astronomy (miscellaneous)FERMION PAIR PRODUCTIONUPGRADETevatronhadron-colliders01 natural sciencesHigh Energy Physics - ExperimentPhysics Particles & Fieldselectron: pair productionHigh Energy Physics - Experiment (hep-ex)MONTE-CARLOUNIVERSAL MONTE-CARLOELECTROMAGNETIC CALORIMETERDZERO[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]HADRON COLLIDERSangular distributionBatavia TEVATRON CollMonte CarloPhysicsscattering [anti-p p]gauge bosonPhysicsElectroweak interactionDrell–Yan processWeinberg anglespontaneous symmetry breaking [electroweak interaction]muon: pair productionPhysical Sciencesmixing angle [electroweak interaction]bosonPHOTOSmass: measured [W]asymmetryParticle physicsFOS: Physical sciencesSEMIANALYTICAL PROGRAMddc:500.2Astronomy & Astrophysicselectroweak interaction: spontaneous symmetry breaking114 Physical sciences530programmingW: mass: measuredStandard Modelanti-p p: colliding beams[ PHYS.HEXP ] Physics [physics]/High Energy Physics - Experiment [hep-ex]hadroproduction [Z0]0103 physical sciencesanti-p p: scatteringddc:530High Energy Physicspair production [electron]pair production [muon]CALORIMETER010306 general physicsQED RADIATIVE-CORRECTIONSQed radiative-corrections; fermion pair production; universal; Monte Carlo; parton distributions; hadron-colliders; electromagnetic; calorimeter;semianalytical programs; E(+)E(-) annihilation; boson; production; D0 detectorGauge bosonBOSON PRODUCTIONMuonScience & Technologyelectroweak interaction: mixing angleAnti-p p: scattering | anti-p p: colliding beams | Z0: hadroproduction | Z0: leptonic decay | electroweak interaction: spontaneous symmetry breaking | electroweak interaction: mixing angle | muon: pair production | W: mass: measured | Weinberg angle | Batavia TEVATRON Coll | angular distribution | electron: pair production | Drell-Yan process | gauge boson | programming | asymmetry | CDF | DZERO | experimental resultsIDENTIFICATION010308 nuclear & particles physicsHigh Energy Physics::PhenomenologyuniversalWeinberg angleZ0: hadroproductionQED RADIATIVE-CORRECTIONS; FERMION PAIR PRODUCTION; UNIVERSAL; MONTE-CARLO; PARTON DISTRIBUTIONS; HADRON COLLIDERS; ELECTROMAGNETIC; CALORIMETER; SEMIANALYTICAL PROGRAM; E(+)E(-) ANNIHILATION; BOSON; PRODUCTION; D0 DETECTORleptonic decay [Z0]E(+)E(-) ANNIHILATIONelectromagneticPARTON DISTRIBUTIONSExperimental High Energy PhysicsZ0: leptonic decayD0 DETECTORCDFHigh Energy Physics::Experimentproductioncolliding beams [anti-p p]Leptonexperimental results
researchProduct

Sivers asymmetry extracted in SIDIS at the hard scales of the Drell-Yan process at COMPASS

2017

Proton transverse-spin azimuthal asymmetries are extracted from the COMPASS 2010 semi-inclusive hadron measurements in deep inelastic muon-nucleon scattering in those four regions of the photon virtuality $Q^2$, which correspond to the four regions of the di-muon mass $\sqrt{Q^2}$ used in the ongoing analysis of the COMPASS Drell-Yan measurements. This allows for a future direct comparison of the nucleon transverse-momentum-dependent parton distribution functions extracted from these two alternative measurements. Various two-dimensional kinematic dependences are presented for the azimuthal asymmetries induced by the Sivers transverse-momentum-dependent parton distribution function. The inte…

Drellâ YanDrell-Yan processPhotonHadronparton: distribution functionDrell-YanPartontransverse momentum dependence01 natural sciencesCOMPASSSIDISHigh Energy Physics - ExperimentSivers functionSubatomär fysikHigh Energy Physics - Experiment (hep-ex)High Energy Physics - Phenomenology (hep-ph)CompassSubatomic Physics[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]dimension: 2Nuclear ExperimentSIDIS; Drell–Yan; Spin; Azimuthal asymmetries; Sivers; TMDsmedia_commonPhysicsQuantum chromodynamicsdeep inelastic scattering: semi-inclusive reactionpolarized target: transversephotonDrell–Yan processhep-phlcsh:QC1-999Drell–YanAzimuthal asymmetrieHigh Energy Physics - PhenomenologykinematicsSiverpolarized beam: longitudinalNucleonAzimuthal asymmetriesspin: asymmetryParticle Physics - ExperimentParticle physicsNuclear and High Energy Physicsangular distribution: asymmetrymedia_common.quotation_subjectFOS: Physical sciencesTMDsAsymmetryNuclear physicsSpin[ PHYS.HEXP ] Physics [physics]/High Energy Physics - Experiment [hep-ex]Azimuthal asymmetries; Drell–Yan; SIDIS; Sivers; Spin; TMDs; Nuclear and High Energy Physics0103 physical sciencesmuon nucleon: deep inelastic scatteringquantum chromodynamicsSiversmuon nucleon: scattering010306 general physicsParticle Physics - Phenomenologynucleon: transverse momentum010308 nuclear & particles physics160 GeV/chep-exCERN SPSmuon+ p: deep inelastic scattering[PHYS.HPHE]Physics [physics]/High Energy Physics - Phenomenology [hep-ph][ PHYS.HPHE ] Physics [physics]/High Energy Physics - Phenomenology [hep-ph]High Energy Physics::Experimentlcsh:Physicsexperimental results
researchProduct

Automated analysis of quetiapine and other antipsychotic drugs in human blood by high performance-liquid chromatography with column-switching and spe…

2004

Abstract An automated HPLC method with column switching is described for the determination of quetiapine, clozapine, perazine, olanzapine and metabolites in blood serum. After clean-up on silica C8 material (20 μm particle size) drugs were separated on ODS Hypersil C18 material (5 μm; column size 250 mm × 4.6 mm i.d.) within 25 min and quantified by ultraviolet (UV) detection at 254 nm. The limit of quantification ranged between 10 and 50 ng/ml. At therapeutic concentrations of the drugs, the inter-assay reproducibility was below 10%. Analyses of drug concentrations in serum of 75–295 patients treated with therapeutic doses of the antipsychotic drugs revealed mean ± S.D. steady state concen…

DrugDibenzothiazepinesmedicine.drug_classmedia_common.quotation_subjectClinical BiochemistryAtypical antipsychoticPharmacologyBiochemistryHigh-performance liquid chromatographyAnalytical ChemistryPerazineBenzodiazepinesQuetiapine FumarateColumn chromatographyBlood serummedicineHumansClozapineChromatography High Pressure Liquidmedia_commonChromatographymedicine.diagnostic_testChemistryReproducibility of ResultsCell BiologyGeneral MedicinePerazineTherapeutic drug monitoringOlanzapineCalibrationQuetiapineSpectrophotometry Ultravioletmedicine.drugAntipsychotic AgentsJournal of chromatography. B, Analytical technologies in the biomedical and life sciences
researchProduct

A Colorimetric Membrane-Based Sensor with Improved Selectivity towards Amphetamine

2021

Due to their simplicity, speed and low cost, chemical spot tests are increasingly demanded for the presumptive identification of illicit drugs in a variety of contexts such as point-of-care assistance or prosecution of drug trafficking. However, most of the colorimetric reactions used in these tests are, at best, drug class selective. Therefore, the development of tests based on chemical reactions with improved discrimination power is of great interest. In this work, we propose a new colorimetric assay for amphetamine (AMP) based on its reaction with solutions of alkaline gold bromide to form an insoluble yellow–orange derivative. The resulting suspensions are then filtered onto nylon membr…

DrugDiffuse reflectance infrared fourier transformmedia_common.quotation_subjectamphetaminePharmaceutical Sciencegold bromideBiosensing TechniquesSensitivity and Specificitycolorimetric sensorsArticleAnalytical ChemistryAbsorbancechemistry.chemical_compoundQD241-441BromideSpectroscopy Fourier Transform InfraredDrug DiscoverymedicinePhysical and Theoretical ChemistryEphedrineAmphetaminemedia_commonChromatographyIllicit DrugsOrganic ChemistryReproducibility of Resultsdrug analysisSubstance Abuse DetectionMembranechemistryChemistry (miscellaneous)Molecular MedicineColorimetryillicit drug samplesSelectivitymedicine.drugMolecules
researchProduct

Aloin delivery on buccal mucosa: ex vivo studies and design of a new locoregional dosing system

2014

Context: Chemoprevention of potential malignant disorders or cancerous lesions that affect oral mucosae requires extended duration of treatment. Locoregional delivery of natural products could represent a promising strategy for this purpose. Objective: To investigate the aptitude of aloin to permeate through, or accumulate in, the buccal mucosa and to develop a new prolonged oro-mucosal drug delivery system. Materials and Methods: Permeation/accumulation of aloin from Curacao Aloe (containing 50% barbaloin) was evaluated ex vivo, using porcine buccal mucosa as the most useful model to simulate human epithelium. Oro-mucosal matrix tablets were prepared by dispersing aloin (10% w/w) in Eudrag…

DrugEmodinPolymersSwinemedia_common.quotation_subjectChemistry PharmaceuticalAcrylic ResinsPharmaceutical ScienceDentistryAloinPharmacologyFriabilityPermeabilityBarbaloin buccal tablets aloin matrix tablets oro-mucosal delivery locoregional drug delivery buccal mucosa.chemistry.chemical_compoundDrug Delivery SystemsSettore MED/28 - Malattie OdontostomatologicheDrug DiscoverymedicineAnimalsDosingAloemedia_commonPharmacologybusiness.industryOrganic ChemistryMouth MucosaAdhesivenessReproducibility of ResultsPermeationDrug LiberationchemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliverySwellingmedicine.symptombusinessEx vivoTablets
researchProduct

Antibacterial drug release from a biphasic gel system: Mathematical modelling

2019

Bacterial infections represent an important drawback in the orthopaedic field, as they can develop either immediately after surgery procedures or after some years. Specifically, in case of implants, they are alleged to be troublesome as their elimination often compels a surgical removal of the infected implant. A possible solution strategy could involve a local coating of the implant by an antibacterial system, which requires to be easily applicable, biocompatible and able to provide the desired release kinetics for the selected antibacterial drug. Thus, this work focusses on a biphasic system made up by a thermo-reversible gel matrix (Poloxamer 407/water system) hosting a dispersed phase (…

DrugMaterials sciencemedia_common.quotation_subjectVancomycin HydrochloridePharmaceutical SciencePoloxamer02 engineering and technologyantibacterial drugengineering.material030226 pharmacology & pharmacyDiffusion03 medical and health scienceschemistry.chemical_compoundDrug Delivery Systems0302 clinical medicineMicro-particleCoatingVancomycinAntibacterial drugmedicineAntibacterial drugmedia_commonGelMathematical modellingReproducibility of ResultsMicro-particlesModels Theoretical021001 nanoscience & nanotechnologyAnti-Bacterial AgentsDrug LiberationKineticsPLGAchemistrySettore CHIM/09 - Farmaceutico Tecnologico Applicativoantibacterial drug; Gels; Mathematical modelling; Micro-particles; Orthopaedic implantsPoloxamer 407engineeringOrthopaedic implantsDelivery systemImplant0210 nano-technologyGelsmedicine.drugBiomedical engineeringInternational Journal of Pharmaceutics
researchProduct

A multilevel object-oriented modelling methodology for physiologically-based pharmacokinetics (PBPK): Evaluation with a semi-mechanistic pharmacokine…

2019

Abstract Background and objective The aims of this study are (i) to assess the predictive reliability of the physiologically based software PhysPK versus the well-known population approach software NONMEM for the cited semi-mechanistic PK model, (ii) to determine whether these modelling approaches are interchangeable and (iii) to compare acausal with causal modelling approaches in the framework of semi-mechanistic PK models. Methods A semi-mechanistic model was proposed, which assumed oral administration of a solid dosage form with a peripheral compartment and two active metabolites. The model incorporates intestinal transit, dissolution limited by solubility, variable efflux transporter ex…

DrugPhysiologically based pharmacokinetic modellingComputer sciencemedia_common.quotation_subjectPopulationCmaxHealth InformaticsModels BiologicalDosage form030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineSoftwarePharmacokineticsPharmacokineticseducationmedia_commonVariable (mathematics)education.field_of_studybusiness.industryReproducibility of ResultsExpression (computer science)Computer Science ApplicationsNONMEMSolubilityArea Under CurvebusinessBiological system030217 neurology & neurosurgerySoftwareComputer methods and programs in biomedicine
researchProduct

ALDEN, an Algorithm for Assessment of Drug Causality in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case–Control Analysis

2010

Epidermal necrolysis (EN)--either Stevens-Johnson syndrome (SJS) or toxic EN (TEN)--is a severe drug reaction. We constructed and evaluated a specific algorithm, algorithm of drug causality for EN (ALDEN), in order to improve the individual assessment of drug causality in EN. ALDEN causality scores were compared with those from the French pharmacovigilance method in 100 cases and the case-control results of the EuroSCAR study. Scores attributed by ALDEN segregated widely. ALDEN pointed to a "probable" or "very probable" causality in 69/100 cases as compared to 23/100 with the French method (P < 0.001). It scored "very unlikely" causality for 64% of medications vs. none with the French metho…

DrugTime FactorsDrug-Related Side Effects and Adverse Reactionsmedia_common.quotation_subjectRecurrenceEpidermal necrolysisPharmacovigilanceProduct Surveillance PostmarketingHumansMedicinePharmacology (medical)Drug reactionProbabilitymedia_commonPharmacologybusiness.industryReproducibility of ResultsStevens johnsonmedicine.diseaseCausalityToxic epidermal necrolysisEuropePharmaceutical PreparationsCase-Control StudiesStevens-Johnson SyndromeCase control analysisFrancebusinessAlgorithmAlgorithmsClinical Pharmacology &amp; Therapeutics
researchProduct